Construction of a Recombinant Phage-vaccine Capable of Reducing the Growth Rate of an Established LL2 Tumor Model.

Over expression of the epidermal growth factor receptor (EGFR) in many human epithelial tumors has been correlated with disease progression and poor prognosis. EGFR-inhibiting immunotherapy has already been introduced in cancer therapy. Peptide displaying phage particles in eukaryotic hosts can behave as antigen carriers, able to activate the innate immune system and to elicit adaptive immunity. Herein, the M13-pAK8-VIII phagemid plasmid was engineered to contain the sequences for an EGFR mimotope along with the L2 extracellular domain of EGFR (EM-L2) which would produce the final peptide-phage vaccine. The prophylactic and therapeutic effects of this novel vaccine were evaluated on the Lewis lung carcinoma induced mouse (C57/BL6) model. The recombinant peptide was confirmed to be displayed on the surface of M13 phage as an extension for phage's PVIII protein. Immunization of mice with peptide-phage vaccine resulted in antibody production against EM-L2 and significant reduction of tumor growth rate by nearly 25 percent. In conclusion, EM-L2 displaying phage particles could be deemed as an encouraging strategy in contemporary cancer immunotherapy.

[1]  H. Modjtahedi,et al.  A novel recombinant anti‐epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model , 2017, Microbiology and immunology.

[2]  Joseph F. Murphy,et al.  Immunotherapy of cancers comes of age , 2017, Expert review of clinical immunology.

[3]  S. Khalili,et al.  Structural analyses of the interactions between the thyme active ingredients and human serum albumin , 2017 .

[4]  I. Rasooli,et al.  In silico design of an immunogen against Acinetobacter baumannii based on a novel model for native structure of Outer membrane protein A. , 2017, Microbial pathogenesis.

[5]  A. Jahangiri,et al.  Structural pierce into molecular mechanism underlying Clostridium perfringens Epsilon toxin function , 2017, Toxicon : official journal of the International Society on Toxinology.

[6]  S. Khalili,et al.  3D structure of DKK1 indicates its involvement in both canonical and non-canonical Wnt pathways , 2017, Molecular Biology.

[7]  B. Baradaran,et al.  Phage display as a promising approach for vaccine development , 2016, Journal of Biomedical Science.

[8]  S. Khalili,et al.  ILP-2 modeling and virtual screening of an FDA-approved library:a possible anticancer therapy. , 2016, Turkish journal of medical sciences.

[9]  A. Pourfathollah,et al.  Key role of Dkk3 protein in inhibition of cancer cell proliferation: An in silico identification. , 2016, Journal of theoretical biology.

[10]  M. R. Bazl,et al.  In Silico and in vitro Evaluation of a Recombinant Fusion Peptide as a Novel Candidate Vaccine for EGFR-positive Tumors , 2016 .

[11]  A. Jahangiri,et al.  In silico analyses of Wilms׳ tumor protein to designing a novel multi-epitope DNA vaccine against cancer. , 2015, Journal of theoretical biology.

[12]  S. Khalili,et al.  Kremen is beyond a subsidiary co-receptor of Wnt signaling: an in silico validation , 2015 .

[13]  M. Rasaee,et al.  Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study , 2015, Immunopharmacology and immunotoxicology.

[14]  I. Rasooli,et al.  Functional Exposed Amino Acids of BauA as Potential Immunogen Against Acinetobacter baumannii , 2015, Acta biotheoretica.

[15]  H. Modjtahedi,et al.  Triple tandem mimotope peptide of Epidermal Growth Factor Receptor displaying on the surface of M13 phage induces anti-tumor response in mice tumor model , 2014 .

[16]  A. Jahangiri,et al.  Computational vaccinology and epitope vaccine design by immunoinformatics. , 2014, Acta microbiologica et immunologica Hungarica.

[17]  H. Modjtahedi,et al.  Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope , 2014, Immunopharmacology and immunotoxicology.

[18]  M. Collins,et al.  DNA fusion vaccine designs to induce tumor‐lytic CD8+ T‐cell attack via the immunodominant cysteine‐containing epitope of NY‐ESO 1 , 2013, International journal of cancer.

[19]  S. Farajnia,et al.  EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[20]  S. Zappavigna,et al.  Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance , 2013, Expert opinion on biological therapy.

[21]  T. Gajewski,et al.  Cancer immunotherapy , 2012, Molecular oncology.

[22]  Fengyu,et al.  Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. , 2011, Vaccine.

[23]  F. Yu,et al.  Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface , 2009, Acta Pharmacologica Sinica.

[24]  K. Wiesmüller,et al.  Mimotope vaccines for cancer immunotherapy. , 2007, Vaccine.

[25]  A. Ullrich,et al.  Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant , 2006, International journal of cancer.

[26]  F. Liu,et al.  Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor1 , 2003, The Journal of Immunology.

[27]  J. Cherrington,et al.  Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents , 2003, Expert opinion on investigational drugs.

[28]  Wei Zhou,et al.  Phage display particles expressing tumor‐specific antigens induce preventive and therapeutic anti‐tumor immunity in murine p815 model , 2002, International journal of cancer.

[29]  R. Jorissen,et al.  Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor , 2008, Protein science : a publication of the Protein Society.

[30]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[31]  H. Modjtahedi,et al.  Anti‐EGFR monoclonal antibodies which act as EGF, TGFα, HB‐EGF and BTC antagonists block the binding of epiregulin to EGFR‐expressing tumours , 1998, International journal of cancer.

[32]  D. Engelman,et al.  Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.

[33]  A. Ullrich,et al.  Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. , 1991, Cell regulation.

[34]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[35]  D. Duś,et al.  LL2 cell line derived from transplantable murine Lewis lung carcinoma--maintenance in vitro and growth characteristics. , 1985, Archivum immunologiae et therapiae experimentalis.